NFE2L2 and breast carcinoma: Thus, the different responses of AREc32 cells and Hepa1c1c7 cells to Nrf2-ARE activation may result from distinct estrogen signaling in these two cell lines (human breast cancer cells versus mouse hepatoma cells).